ITGA7 interacts with FN1 to suppress the PI3K/AKT signaling pathway and inhibit thyroid cancer progression Authors: Hui Yu, Lei Chen, Tao Ma, QiLun Liu, FaXuan Wang Published: 2026 ABSTRACT AbstractObjectiveThyroid cancer (TC) is the most common malignant tumor of the endocrine system, and its incidence has increased annually. Although TC generally has a favorable prognosis, some patients experience recurrence after treatment. Therefore, understanding the pathogenic mechanisms of TC is crucial for improving its treatment. It was hypothesized that ITGA7 suppresses TC by binding to FN1 and inhibiting the PI3K/AKT pathway. This study aimed to test this hypothesis and elucidate the underlying mechanism.MethodsExpression of Integrin Subunit Alpha 7 (ITGA7) and Fibronectin 1 (FN1) was evaluated in paired samples of normal thyroid and TC tissues via reverse transcription quantitative real-time PCR (RT-qPCR) and immunohistochemistry (IHC). ITGA7 and FN1 mRNA and protein levels were further assessed using RT-qPCR and Western blot analysis. Functional assays included Cell Counting Kit-8 for cell viability, 5-Ethynyl-2’-deoxyuridine (EdU) incorporation for proliferation, Transwell for migration and invasion, and flow cytometry for apoptosis. Protein interaction and co-localization between ITGA7 and FN1 were confirmed through co-immunoprecipitation and immunofluorescence (IF). Western blot was used to examine Phosphatidylinositol 3-kinase/Protein Kinase B (PI3K/AKT) signaling pathway components, and IHC was applied to assess related protein expression in clinical specimens. A xenograft model in nude mice was established to investigate the role of ITGA7 in tumor growth in vivo. Bioinformatics tools including STRING and GEPIA were utilized to predict potential interactions involving ITGA7.ResultsRT-qPCR and IHC revealed decreased ITGA7 expression in TC compared to adjacent normal tissues. Consistent downregulation was observed at both mRNA and protein levels in TC cell lines. Functional loss-of-function experiments showed that ITGA7 knockdown enhanced viability, proliferation, migration, and invasion, and suppressed apoptosis. FN1 was identified as an ITGA7-binding partner with negatively correlated expression. FN1 was upregulated in TC tissues, and its silencing impeded malignant phenotypes including proliferation and migration, while promoting apoptosis. The protein interaction and co-localization between ITGA7 and FN1 were experimentally validated. Western blot analysis demonstrated that silencing ITGA7 upregulated FN1 and activated the PI3K/AKT pathway. Conversely, FN1 knockdown suppressed pathway activity. In vivo studies confirmed that ITGA7 suppressed tumor progression by inhibiting the FN1-mediated activation of the PI3K/AKT pathway. Rescue assays demonstrated that FN1 depletion counteracted the oncogenic effects of ITGA7 silencing.ConclusionThe expression of ITGA7 in TC tissues and cells was significantly lower than that in normal tissues and cells. ITGA7 inhibits TC progression by interacting with FN1 and suppressing PI3K/AKT signaling pathway activation.Graphical abstract A graphical abstract summarizing the mechanism of ITGA7/FN1/PI3K/AKT axis in TC progression Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1007/s00432-026-06531-8.Keywords: FN1, ITGA7, Thyroid cancer, PI3K/AKT signaling pathway Introduction Thyroid cancer (TC) represents one of the most common malignancies affecting the endocrine system, with a steadily rising global incidence (Cherella et al. 2021). Epidemiological studies indicate that the incidence of TC is increasing at an annual rate of nearly 4%, and projections suggest that by 2030, it could surpass colorectal cancer to become the fourth most commonly diagnosed cancer worldwide (Rahib et al. 2014). TC is generally categorized into four major subtypes: papillary thyroid carcinoma (PTC), follicular thyroid carcinoma (FTC), anaplastic thyroid carcinoma, and medullary thyroid carcinoma. Among these, PTC and FTC are classified as differentiated TC, which represents the predominant form of the disease, making them the most common histological types (Zheng et al. 2023; Kapiteijn et al. 2012). Approximately 80% of diagnosed TC cases are PTC. Although the 5-year survival rate exceeds 90% after treatment, indicating a favorable prognosis, post-treatment recurrence still occurs in some patients (Vecchia et al. 2015; Milano 2018). Therefore, understanding the pathogenic mechanisms underlying TC is essential for the development of innovative therapeutic strategies and the enhancement of cure rates. Integrins are a large family of adhesion and signaling proteins, comprising α (ITGA) and β (ITGB) subunits, which are primarily involved in cell–matrix interactions and cell–cell adhesion (Cooper and Giancotti 2019). Recent research has increasingly highlighted the significance of aberrant integrin expression in tumorigenesis, angiogenesis, and the proliferation, migration, and invasion of cancer cells (Liu et al. 2023). Integrin Subunit Alpha 7 (ITGA7), encoded by a gene located on chromosome 12q13.2 (Ziober et al. 1999), exhibits dual roles across various cancer types. Notably, ITGA7 functions as an oncogene in tongue squamous cell carcinoma (Lv et al. 2020), hepatocellular carcinoma (Ge et al. 2020), endometrial carcinoma (Liang et al. 2023), and glioblastoma (Haas et al. 2017), where its overexpression facilitates cancer progression. Conversely, in breast cancer (Bhandari et al. 2018), PTC (Guan et al. 2020), prostate cancer (Tan et al. 2013), and malignant pleural mesothelioma (Laszlo et al. 2015), ITGA7 plays a role in suppressing tumors, impeding cancer development. In PTC, ITGA7 inhibits tumor progression by modulating epithelial-mesenchymal transition. Despite reports of ITGA7 downregulation in TC tissues and cells, the precise mechanisms underlying this phenomenon remain inadequately elucidated. Fibronectin 1 (FN1) is a versatile glycoprotein found in the extracellular matrix (ECM) with a molecular weight ranging between 250 and 270 kDa. It is predominantly synthesized by fibroblasts, endothelial cells, and epithelial cells (Mosher et al. 1991; Spada et al. 2021). FN1 exists in plasma as soluble dimers and is also present as dimers or multimers on cell surfaces and within the ECM (Geng et al. 2021). This protein plays essential roles in multiple physiological processes, including embryogenesis, wound healing, blood clotting, immune responses, and tumor cell adhesion during cancer proliferation and metastasis (Pankov and Yamada 2002). Substantial evidence indicates that FN1 interacts with cell-surface integrins to influence tumor progression. For example, its upregulation promotes progression in colorectal cancer (Cai et al. 2018), gastric cancer (Pan et al. 2023), and TC (Wu et al. 2020), as well as angiogenesis (Xu et al. 2023), while paradoxically suppressing progression and metastasis in melanoma (Liu et al. 2008). As a central regulator, the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) signaling pathway modulates essential cellular functions such as proliferation, growth, migration, and metabolism (Yang et al. 2019). Structurally, PI3K exists as a membrane-associated enzyme comprising three distinct classes (I–III), among which class I has received predominant research attention. Activation of receptor tyrosine kinases initiates a biochemical cascade wherein PI3K mediates the conversion of phosphatidylinositol-4,5-bisphosphate to phosphatidylinositol-3,4,5-trisphosphate via phosphorylation. Subsequent phosphatidylinositol (3,4,5)-trisphosphate (PIP3) accumulation serves as a membrane docking site for AKT, enabling its phosphorylation and subsequent activation of diverse downstream targets (Wymann et al. 2003). Extensive experimental evidence has firmly established the pivotal involvement of this signaling axis in the pathogenesis of various malignancies (Zhou et al. 2025; Wang et al. 2022; Deng and Zhou 2023). Furthermore, ITGA7 has been shown to interact with CKAP4, thereby inhibiting PI3K/AKT signaling (Wang et al. 2024). This finding raises questions about whether a similar regulatory mechanism exists in the context of the interaction between ITGA7 and FN1. However, the specific molecular mechanism underlying the interaction between ITGA7 and FN1 in TC remains unclear. Therefore, in this study, it was hypothesized that ITGA7 binds to FN1 and inhibits the PI3K/AKT signaling pathway, thereby slowing TC progression and exerting a tumor-suppressive effect. To test this hypothesis, the aberrant expression of ITGA7 in TC tissues and cells was initially validated using reverse transcription quantitative real-time PCR (RT-qPCR). Functional assays further demonstrated the effects of ITGA7 and FN1 on TC malignancy. The influence of ITGA7 and FN1 on the PI3K/AKT signaling pathway was subsequently examined. Although KTC-1 is derived from poorly differentiated thyroid cancer (PDTC), it shares key molecular features with TC, including the expression patterns of ITGA7 and FN1, and thus serves as a valid model for studying TC pathogenesis. Materials and methods Tissue samples To investigate the expression profiles of ITGA7 and FN1, paired clinical specimens, including TC tissues and their matched adjacent non-tumorous tissues, were collected from 30 patients who received treatment at the General Hospital of Ningxia Medical University. Clinical data for all participants were collected, including age, sex, tumor size, TNM stage, and lymph node metastasis status. The detailed distribution of these clinicopathological characteristics is shown in Table 1. For subsequent studies, the collected tissues were instantly frozen and preserved in liquid nitrogen. Total RNA was extracted from these tissue specimens and subjected to RT-qPCR to determine the mRNA expression levels of ITGA7 and FN1. Meanwhile, immunohistochemical (IHC) staining was performed in parallel to assess both the spatial localization and protein expression levels of these two markers. This study received approval from the Ethics Committee of the General Hospital of Ningxia Medical University, and all enrolled participants provided written informed consent. All experimental procedures were carried out in strict compliance with institutional and national ethical standards. Table 1Characteristics of thyroid cancer patients (n = 30)VariableN (%)Age (years) ≤ 5520 (66.7) > 5510 (33.3)Sex Male6 (20.0) Female24 (80.0)Tumor size (mm) < 111 (36.7) ≥ 119 (63.3)TNM Stage I–II17 (56.7) III–IV13 (43.3)Lymph node metastasis Yes14 (46.7) No16 (53.3)TNM Tumor Node Metastasis Characteristics of thyroid cancer patients (n = 30) TNM Tumor Node Metastasis Cell culture A normal thyroid cell line (Nthy-ori 3–1) and three TC cell lines—Kobe Thyroid Cancer-1 (KTC-1), BCPAP (a papillary TC cell line), and Thyroid Papillary Carcinoma-1 (TPC-1)—were obtained from Gibco (Thermo Fisher Scientific, USA). TC cell lines were cultured in Dulbecco’s Modified Eagle Medium (DMEM; Thermo Fisher Scientific, USA), which served as the basal medium. To support cell growth, 1% penicillin–streptomycin and 10% fetal bovine serum (FBS)—both purchased from Thermo Fisher Scientific (Gibco)—were added to the DMEM. By contrast, the normal Nthy-ori 3–1 cells were maintained in Roswell Park Memorial Institute-1640 medium (Thermo Fisher Scientific, Gibco), which contained the same supplements (1% penicillin–streptomycin and 10% FBS) to support cell growth. A dedicated incubator was used to incubate all cell lines at 37 °C. The environment was controlled to maintain 5% CO₂ and 95% humidity (Zheng et al. 2023). Cell transfection KTC-1 cells were seeded in 6-well plates at 1 × 10⁶ cells per well and cultured overnight under standard conditions. For transient transfection, short hairpin RNAs (shRNAs) with specific targeting of ITGA7 (sh-ITGA7) and FN1 (sh-FN1), along with a negative control shRNA (sh-NC), were introduced into KTC-1 cells at a final concentration of 50 nM. The transfection process used Lipofectamine 3000 (Invitrogen Life Technologies, USA) as the transfection reagent. At 6 h post-transfection initiation, the culture medium was replaced with fresh medium. At 48 h post-transfection, cells were harvested to evaluate gene silencing efficiency using RT-qPCR and Western blot. For the establishment of stable knockdown cell lines, KTC-1 cells were infected with lentiviral vectors carrying sh-FN1 or the control sh-NC. Stable cell lines expressing sh-FN1 were obtained by selecting with puromycin at a concentration of 2 μg/mL. All shRNAs used in this experiment were synthesized by RiboBio (China), while lentiviral plasmids were acquired from GENE Company (China). RT-qPCR Total RNA was isolated from cells using TRIzol reagent (Thermo, USA). The isolated RNA was then reverse-transcribed into complementary DNA (cDNA) with the TransScript All-in-One First-Strand cDNA Synthesis SuperMix for RT-PCR kit (TransGen Biotech, China). qPCR was conducted using qPCR SYBR Green Premix (Vazyme, China) on a Step-One Plus Real-Time PCR System (Thermo). Each sample was analyzed in triplicate to ensure technical reproducibility. The relative mRNA expression levels were calculated via the 2−ΔΔCt method, with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) used as the internal reference gene to normalize expression (Zheng et al. 2023). The sequences of primers used are listed in Table 2. Table 2Primer Sequences for RT-qPCRGenePrimer sequence (5′→3′)ITGA7Forward: GCTGTGAAGTCCCTGGAAGTGATTReverse: GCATCTCGGAGCATCAAGTTCTTFN1Forward: AGGAAGCCGAGGTTTTAACTGReverse: AGGACGCTCATAAGTGTCACCGAPDHForward: GTCTCCTCTGACTTCAACAGCGReverse: ACCACCCTGTTGCTGTAGCCAA Primer Sequences for RT-qPCR Cell counting kit-8 (CCK-8) assay Cell viability was assessed using a CCK-8 kit. For the assay, transfected cells were first seeded into 96-well plates at a density of 2 × 103 cells per well, then cultured under standard conditions (37 °C, 5% CO₂) for a maximum duration of 84 h. Once the preset culture period was completed, 10 µL of CCK-8 reagent was added to each well, and the plates were incubated for an additional 4 h to ensure sufficient reaction between the reagent and viable cells. Finally, a microplate reader (BioTek, USA) was used to measure the absorbance at a wavelength of 450 nm (Li et al. 2018). 5-Ethynyl-2'-deoxyuridine (EdU) assay The EdU incorporation assay kit (RiboBio) was used to assess cell proliferation, following the protocol recommended by the manufacturer. Cells in the exponential growth phase were placed into 96-well plates at a density of 1 × 104 cells per well and incubated overnight at 37°C with 5% CO₂ to facilitate adherence and stable growth. For proliferation labeling, 100 μL of 10 μM EdU solution was added to each well, and the cells were incubated at 37°C for 2 h to allow EdU incorporation into newly synthesized DNA. After removing the labeling medium, the cells were rinsed three times with phosphate-buffered saline (PBS) to eliminate residual EdU solution that might interfere with subsequent steps. Next, the cells were fixed with 4% paraformaldehyde at room temperature for 15 min; after fixation, 50 μL of reaction mixture was added to each well, followed by a 30-min incubation to complete the labeling reaction. To visualize all cell nuclei for quantitative comparison, nuclear counterstaining was conducted using 4′,6-diamidino-2-phenylindole (DAPI). Fluorescent images were captured using an Olympus microscope system, and quantitative analysis of cell proliferation was performed with ImageJ software. The proliferation rate was determined as the percentage of EdU-positive nuclei relative to the total number of DAPI-stained nuclei, with measurements collected across multiple microscopic fields to ensure data representativeness (Li et al. 2022). In addition, quantitative analysis of EdU was performed by measuring the mean fluorescence intensity using ImageJ software. Transwell assay Cell migration and invasion were evaluated using Transwell chambers (Corning, USA). For the invasion assay, polycarbonate membranes were coated with Matrigel (Corning). Adherent cells were harvested, resuspended in serum-free medium, and plated at 1 × 105 cells per well in the upper chamber, while the lower chamber contained medium with 10% FBS to create a chemotactic gradient. After 24 h at 37°C, non-migratory cells on the upper membrane were wiped away, and the cells that migrated to the lower side were fixed with 4% paraformaldehyde and stained with 0.1% crystal violet for imaging. The migration assay followed the same protocol but without Matrigel to assess motility. Transmigrated cells were quantified to evaluate metastatic potential (Li et al. 2022). Quantitative analysis was performed using ImageJ software. Cell apoptosis detection An Annexin V-FITC/propidium iodide (PI) apoptosis detection kit (KeyGen Biotech, China) was employed to assess cellular apoptosis. After completing the experimental treatments, cells were rinsed twice with ice-cold PBS to remove residual culture medium, then resuspended in 500 μL of 1 × binding buffer to prepare uniform cell suspensions. For fluorescence labeling, each cell suspension was supplemented with 5 μL of Annexin V-FITC and 5 μL of PI. The mixtures were then incubated at 25 °C for 15 min under light-protected conditions to prevent fluorescence signal quenching. Subsequent analysis of the samples was performed using a BD FACS Aria III flow cytometer (BD Biosciences, USA), with a minimum of 10,000 cellular events collected per sample to ensure statistical reliability (Kang et al. 2022). Western blot After transfection, cells were harvested and lysed in radioimmunoprecipitation assay (RIPA) buffer (Beyotime), which was supplemented with protease and phosphatase inhibitors to prevent protein degradation and dephosphorylation. Protein concentration was determined with a bicinchoninic acid protein assay kit (Thermo). Equal protein aliquots (30 μg) were resolved on 10% sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE; Bio-Rad, USA) and electrophoretically transferred to polyvinylidene difluoride membranes (Millipore, USA). The membranes were blocked with 5% non-fat milk for 1 h at room temperature and then probed with primary antibodies diluted at 1:1000, which were incubated at 4 °C overnight. Primary antibodies included those against: ITGA7 (bs-1816R, Bioss, China), FN1 (A12977, ABclonal, China), PI3K (ab86714, Abcam, USA), phospho-PI3K (p-PI3K; ab182651, Abcam, USA), AKT (60,203–2-Ig, Proteintech, USA), phospho-AKT (p-AKT; ab38449, Abcam, USA), and GAPDH (FD0063, FDbio, China). Thereafter, the membranes were incubated for 1 h at room temperature with horseradish peroxidase (HRP)-conjugated secondary antibodies (Cell Signaling Technology, USA) at a 1:5000 dilution. Immunoreactive bands were visualized using an enhanced chemiluminescence detection reagent (Millipore, USA, #WBKLS0100) and imaged with a gel documentation system (UVP, USA). GAPDH served as the internal control for protein loading, and the intensity of target protein bands was quantified using ImageJ software (version 1.8.0) (Wang et al. 2024). Immunofluorescence assay Transfected cells with robust growth status were seeded into 24-well plates at a density of 3 × 104 cells per well and cultured overnight to allow sufficient adherence to the plate surface. After adherence, the cells were first fixed with 4% paraformaldehyde and then permeabilized using Triton X-100; subsequent to these steps, the cells were rinsed with PBS and blocked with 1% bovine serum albumin (BSA) at room temperature for 2 h to reduce non-specific antibody binding. Following the blocking step, the cells were incubated overnight at 4 °C with primary antibodies (all diluted at 1:500). The primary antibodies used included those targeting ITGA7 (ab203254, Abcam), FN1 (A12977, ABclonal, China), p-PI3K (ab191606, Abcam), and p-AKT (Ser473, Cell Signaling Technology). After rinsing off unbound primary antibodies, the samples were incubated with fluorescence-conjugated secondary antibodies at room temperature for 1 h under light-protected conditions (to prevent fluorescence quenching). The secondary antibodies—goat anti-rabbit immunoglobulin G (IgG; ab6939, Abcam) and goat anti-mouse IgG (ab97035, Abcam)—were also diluted at 1:500. Finally, cell nuclei were labeled with DAPI, and fluorescent images were captured using a fluorescence microscope (Olympus, Japan) (Zhang et al. 2019). Co-immunoprecipitation (Co-IP) Cellular proteins were isolated using RIPA lysis buffer. The resulting protein lysate was centrifuged at 4 °C to separate insoluble cellular debris from the soluble fraction, and the supernatant was collected for subsequent steps. The supernatant was incubated for 2 h with either anti-ITGA7 antibody (ab203254, Abcam) or control IgG (#AC005, ABclonal, USA), each diluted at 1:500. Protein A/G agarose beads (#sc-2003, Santa Cruz, USA) were then introduced and the mixture was incubated overnight at 4 °C. The beads were subsequently washed multiple times with ice-cold RIPA buffer to eliminate non-specifically bound proteins. After adding loading buffer, the samples were heated to denature the proteins. Finally, eluted proteins (20 μg per sample) were subjected to Western blot analysis (Yang et al. 2020). Subcutaneous xenograft mouse model The animal experiments conducted in this study received approval from the Animal Care and Use Committee of General Hospital of Ningxia Medical University. A total of twelve female BALB/c nude mice, aged between 4 and 6 weeks and weighing 18–20 g, were procured from Shanghai SLAC Laboratory Animal Co. Ltd (China). A specific pathogen-free environment was maintained for all animals, featuring 50% humidity and a 12-h/12-h light–dark cycle. After a one-week acclimatization period, the mice were randomly divided into two experimental groups (n = 6 per group): the NC group (sh-NC) and the sh-ITGA7 group. KTC-1 cells, stably transfected with either ITGA7-targeting shRNA (sh-ITGA7) or negative control shRNA (sh-NC), were subcutaneously inoculated into the dorsal flank of each mouse at a concentration of 5 × 10⁶ cells per 100 μL of PBS. Tumor growth was monitored regularly, with volume measurements taken weekly using the formula: (short diameter)2 × ½(long diameter), expressed in mm3. Four weeks following injection, all mice were euthanized via cervical dislocation under anesthesia induced with 10% isoflurane (RWD, #R510-22-10). Tumor weight, measured in milligrams, was recorded, and tumor tissues were subsequently frozen for further experimental analysis (Liu et al. 2025). Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining Apoptosis in tumor tissue sections was detected using a TUNEL kit (Roche, Basel, Switzerland) according to the manufacturer's instructions. Briefly, paraffin-embedded tumor Sects. (4 μm) were deparaffinized, rehydrated, and treated with proteinase K for 15 min at 37 °C. After washing, sections were incubated with TUNEL reaction mixture for 1 h at 37 °C. Hematoxylin was used for nuclear counterstaining, and chromogenic detection was conducted with a 3,3'-Diaminobenzidine substrate kit (Proteintech). Immunoreactivity was examined and imaged under a microscope (DMi1; Leica, USA). The apoptotic index was calculated as the percentage of TUNEL-positive cells relative to total cells in at least five random high-power fields (200 ×) per section. Three sections per mouse (n = 6 mice per group) were analyzed. Data are presented as mean ± SD, and statistical significance was determined by unpaired two-tailed Student’s t-test. IHC For IHC analysis, tumor samples were initially fixed in 4% paraformaldehyde, followed by dehydration, paraffin embedding, and slicing into 4 μm sections. The sections underwent deparaffinization, rehydration, inhibition of endogenous peroxidase, and antigen retrieval. Thereafter, permeabilization was carried out using 0.5% Triton X-100, and nonspecific binding sites were blocked with 1% BSA. Primary antibodies targeting FN1 (15,613–1-AP, Proteintech), ITGA7 (ab203254, Abcam), phospho-PI3K (ab182651, Abcam), and phospho-AKT (ab38449, Abcam) were applied and incubated with the sections for 2 h. After washing, HRP-conjugated secondary antibodies were applied for 30 min (Cell Signaling Technology). Hematoxylin was used for nuclear counterstaining, and chromogenic detection was conducted with a 3,3'-Diaminobenzidine substrate kit (Proteintech). Immunoreactivity was examined and imaged under a microscope (DMi1; Leica, USA) (Zhu et al. 2022). Quantitative analysis was performed using ImageJ software. Data analysis Statistical analysis was carried out with GraphPad Prism software (version 10.0; GraphPad Software, USA). Cell experiments were performed with at least three independent replicates (n = 3), animal experiments with six mice per group (n = 6), and clinical samples included 30 pairs of cancerous and adjacent normal tissues (n = 30). Data are expressed as mean ± standard deviation (mean ± SD). Differences between two groups were assessed using Student’s t-test. For comparisons involving more than two groups, one-way or two-way analysis of variance was employed as appropriate. Survival rates were evaluated by the Kaplan–Meier method. A P-value of less than 0.05 was regarded as statistically significant. Results ITGA7 is downregulated in TC tissues and cells The Gene Expression Profiling Interactive Analysis (GEPIA) database indicated reduced ITGA7 expression in thyroid carcinoma tissues (Fig. 1A). To investigate the functional role of ITGA7 in TC, its expression was examined in tissue samples from 30 TC patients using RT-qPCR and IHC. Both assays consistently showed significantly lower ITGA7 expression in tumor tissues compared to adjacent non-cancerous thyroid tissues (Fig. 1B, C). Further assessment via RT-qPCR and Western blot in normal thyroid epithelial cells and multiple TC cell lines revealed decreased ITGA7 expression in malignant cells relative to normal controls (Fig. 1D, E). Among the TC lines evaluated, KTC-1 exhibited relatively high ITGA7 levels and was therefore selected for subsequent functional studies. Figure 1F shows that lower ITGA7 expression correlates with worse overall survival in TC patients. To explore the biological effects of ITGA7, knockdown was performed in KTC-1 cells using shRNA targeting ITGA7. Transfection efficiency was confirmed by RT-qPCR and Western blot, which demonstrated a significant reduction in both ITGA7 mRNA and protein levels compared to the sh-NC group (Fig. 1G). ITGA7 is downregulated and FN1 is upregulated in TC tissues and cells. A Expression levels of ITGA7 and FN1 in normal thyroid tissues and TC tissues from GEPIA; B RT-qPCR analysis of ITGA7 and FN1 expression in normal thyroid tissues and TC tissues; C IHC staining of ITGA7 and FN1 in normal thyroid tissues and TC tissues (scale bar: 50 μm); D, E RT-qPCR and Western blot analysis of ITGA7 expression in normal thyroid cells and TC cells; F Kaplan–Meier survival analysis; G RT-qPCR and Western blot analysis of ITGA7 expression in TC cells after ITGA7 knockdown. Note: Clinical samples included 30 pairs of cancerous and adjacent normal tissues (n = 30). Cell experiments were independently repeated at least three times (n = 3). Comparisons between groups were performed using paired t-tests and one-way ANOVA. Survival analysis was conducted using the log-rank test. Data are presented as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 ITGA7 silencing promotes TC development To investigate the functional role of ITGA7 in TC, a series of in vitro experiments was conducted. Cell proliferation was assessed using CCK-8 and EdU incorporation assays. As illustrated in Fig. 2A, ITGA7 knockdown significantly increased the proliferative capacity of KTC-1 cells in the CCK-8 assay. Consistent with these findings, EdU staining demonstrated a higher percentage of DNA-replicating cells following ITGA7 suppression (Fig. 2B), supporting the conclusion that ITGA7 suppresses TC cell growth. Further investigation of metastatic potential was performed using Transwell migration and invasion assays. Silencing ITGA7 led to a notable increase in both migratory and invasive cell populations (Fig. 2C, D), suggesting its role in suppressing TC cell motility. Additionally, flow cytometric analysis with Annexin V/PI staining revealed that ITGA7 depletion reduced apoptotic rates in KTC-1 cells (Fig. 2E), indicating its involvement in apoptosis regulation. Collectively, these findings demonstrate that reduced ITGA7 expression enhances proliferative, migratory, and invasive capabilities while inhibiting apoptosis in TC cells, which supports its potential tumor-suppressive function. Downregulation of ITGA7 promotes proliferation, migration and invasion in TC cells. A CCK-8 assay evaluating the effect of ITGA7 on cell viability; B EdU assay assessing the effect of ITGA7 on cell proliferation (scale bar: 20 μm); C, D Transwell assay examining the effect of ITGA7 on cell migration and invasion (scale bar: 20 μm); E Flow cytometry analyzing the effect of ITGA7 on cell apoptosis. Note: Cell experiments were independently repeated at least three times (n = 3). Comparisons between groups were performed using independent samples t-test and two-way ANOVA. Data are presented as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 FN1 knockdown suppresses TC cell development Potential interacting proteins of ITGA7 were identified through the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) database, with results suggesting a binding relationship between ITGA7 and FN1 (Fig. 3A). Subsequent analysis using the GEPIA platform demonstrated that FN1 is markedly elevated in thyroid carcinoma and exhibits a negative correlation with ITGA7 expression in TC samples (Fig. 3B, C). Furthermore, RT-qPCR and IHC staining performed on clinical specimens from 30 TC patients confirmed that FN1 expression was significantly upregulated in tumor tissues compared to adjacent normal tissues (Fig. 3D, E). Based on earlier studies indicating cell type-specific FN1 expression, KTC-1 cells were selected for further functional investigation. To silence FN1, sh-FN1 was introduced into KTC-1 cells, with sh-NC as a control. Transfection efficiency was validated via RT-qPCR and Western blot, both confirming a substantial reduction in FN1 at the transcript and protein levels (Fig. 3F). Proliferation was examined with CCK-8 and EdU incorporation assays, which revealed that FN1 knockdown led to impaired viability and a lower rate of DNA synthesis (Fig. 3G, H). Transwell migration and invasion tests indicated a marked decrease in cell motility and invasiveness upon FN1 suppression (Fig. 3I, J). Additionally, flow cytometric apoptosis analysis showed that reduced FN1 expression resulted in elevated apoptotic rates in KTC-1 cells (Fig. 3K). In summary, these results demonstrate that silencing FN1 significantly restrains proliferative, migratory, and invasive activities, and induces apoptosis in KTC-1 cells, underscoring its critical role in TC progression. Reduced FN1 expression suppresses TC development. A Potential proteins interacting with ITGA7; B FN1 expression in normal thyroid tissues and thyroid carcinoma tissues from the GEPIA database; C Correlation between ITGA7 and FN1 expression; D FN1 expression in normal thyroid and TC tissues detected by RT-qPCR; E FN1 expression in normal thyroid and TC tissues detected by IHC (scale bar: 50 μm); F Transfection efficiency of FN1 shRNA verified by RT-qPCR and Western blot; G Cell viability after FN1 knockdown detected by CCK-8 assay; H Cell proliferation after FN1 knockdown detected by EdU assay (scale bar: 20 μm); I, J Cell migration and invasion abilities after FN1 knockdown evaluated by Transwell assay (scale bar: 20 μm); K Apoptosis after FN1 knockdown detected by flow cytometry. Note: Clinical samples included 30 pairs of cancerous and adjacent normal tissues (n = 30). Cell experiments were independently repeated at least three times (n = 3). Comparisons between groups were performed using independent samples t-test, one-way ANOVA, and Pearson correlation analysis for correlation. Data are presented as mean ± SD. *P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 ITGA7 interacts with FN1 to regulate the PI3K/AKT signaling pathway Based on the preceding findings, both FN1 and ITGA7 were found to modulate the progression of TC. However, whether these two molecules function in a coordinated manner during TC pathogenesis remains to be fully elucidated. To explore this possibility, the relationship between ITGA7 and FN1 was examined using RT-qPCR and Western blot. qPCR analysis revealed that knockdown of ITGA7 led to a notable increase in FN1 mRNA expression (Fig. 4A). Consistent with this, Western blot results demonstrated a marked upregulation of FN1 protein levels following ITGA7 silencing (Fig. 4B). To further validate the physical interaction between ITGA7 and FN1, co-immunoprecipitation and immunofluorescence assays were conducted. These experiments confirmed that ITGA7 and FN1 directly interact and exhibit co-localization, with an inverse correlation in their expression patterns (Fig. 4C, D). Together, these data suggest that ITGA7 binds to FN1 and suppresses its expression. Previous reports indicate that reduced ITGA7 expression facilitates activation of the PI3K/AKT pathway, which contributes to suppressed proliferation and migration in colorectal cancer models (Wang et al. 2024). FN1 is known to be overexpressed in TC, which enhances tumor progression (Geng et al. 2021). To determine whether FN1 promotes TC development via ITGA7-mediated modulation of the PI3K/AKT pathway, Western blot was employed to evaluate the levels of PI3K/AKT signaling proteins in KTC-1 cells after ITGA7 knockdown or FN1 silencing. Results showed that ITGA7 depletion enhanced the expression of PI3K/AKT-related proteins, whereas FN1 knockdown reduced their abundance (Fig. 4E, F). These findings support the conclusion that ITGA7 interacts with FN1 to regulate the PI3K/AKT signaling pathway. ITGA7 interacts with FN1 to regulate the PI3K/AKT signaling pathway. A RT-qPCR analysis of FN1 mRNA levels after ITGA7 silencing; B Western blot detection of FN1 protein expression following ITGA7 knockdown; C Co-IP validation of the interaction between ITGA7 and FN1; D IF confirmation of ITGA7-FN1 interaction and co-localization (scale bar: 20 μm); E, F Western blot analysis of PI3K/AKT pathway-related protein expression. Note: Cell experiments were independently repeated at least three times (n = 3). Comparisons between groups were performed using independent samples t-test and one-way ANOVA. Data are presented as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 Downregulation of FN1 reverses the promoting effects of ITGA7 silencing on TC development and PI3K/AKT signaling activation To further explore the functional roles of ITGA7 and FN1 in TC progression, rescue experiments were conducted. The EdU incorporation assay was used to measure cell proliferation, and Transwell chambers were employed to assess migratory and invasive abilities. Compared with the NC group, FN1 knockdown markedly inhibited proliferation, as evidenced by a decrease in EdU-positive cells, and also reduced cellular migration and invasion (Fig. 5A–C). In contrast, ITGA7 silencing enhanced these malignant phenotypes. However, concurrent knockdown of FN1 and ITGA7 (sh-FN1 + sh-ITGA7) significantly attenuated the promotive effects observed in the sh-ITGA7 group, resulting in suppressed proliferation, migration, and invasion. The phosphorylation status of key signaling molecules was assessed by Western blot (Fig. 5D). Silencing FN1 reduced the expression of p-PI3K and p-AKT relative to the NC group. Conversely, ITGA7 knockdown increased the levels of these phosphorylated proteins. Notably, co-silencing FN1 and ITGA7 counteracted the increase in p-PI3K and p-AKT induced by sh-ITGA7 alone. Collectively, these results indicate that FN1 knockdown reversed the promoting effects of ITGA7 deficiency on TC cell proliferation, migration, invasion, and PI3K/AKT pathway activation. FN1 reverses ITGA7-mediated suppression of TC development and PI3K/AKT signaling. A EdU assay for cell proliferation detection (scale bar: 20 μm); B, C Transwell assay for cell migration and invasion analysis (scale bar: 20 μm); D Western blot analysis of PI3K/AKT signaling pathway-related protein expression. Note: Cell experiments were independently repeated at least three times (n = 3). Comparisons between groups were performed using one-way ANOVA. Data are presented as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 In vivo tumorigenesis assay demonstrates ITGA7’s regulatory role in TC cell malignancy To investigate the role of ITGA7 in thyroid tumorigenesis, an in vivo xenograft model was generated by subcutaneously injecting immunodeficient mice with KTC-1 cells stably transfected with ITGA7-targeting shRNA. Tumor progression was systematically tracked, with measurements of volume and weight recorded at predetermined intervals. Compared with the control group, both the weight and volume of tumor tissues were significantly increased after ITGA7 knockdown (Fig. 6A, B). Subsequently, IHC was performed to detect the expression of ITGA7 and FN1 in mouse tumor tissues. As shown in Fig. 6C, ITGA7 expression was markedly decreased while FN1 expression was significantly increased in tumor tissues following ITGA7 knockdown. Western blot results revealed that after ITGA7 knockdown, the expression levels of FN1 and PI3K/AKT-related proteins were significantly elevated in mouse tumor tissues (Fig. 6D). TUNEL staining of xenograft tumor sections revealed that ITGA7 knockdown significantly reduced the number of apoptotic cells compared with the control group (Fig. 6E). These findings corroborate the proposed mechanism wherein ITGA7 exerts regulatory control over FN1 expression, subsequently influencing PI3K/AKT pathway activity and contributing to the malignant progression of TC. In Vivo tumorigenesis assay demonstrates ITGA7’s regulatory role in TC cell malignancy. A Tumor volume; B Tumor weight; C IHC detection of ITGA7 and FN1 expression in tumor tissue (scale bar: 50 μm); D Western blot analysis of FN1 and PI3K/AKT pathway-related protein expression; E TUNEL assay for detecting the apoptotic cell ratio in tumor tissue (scale bar: 50 μm). Note: Each group contained six mice (n = 6). Comparisons between groups were performed using independent samples t-test and two-way ANOVA. Data are presented as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 Discussion The incidence of TC has been rising at an annual rate of 4%, with projections indicating that it will become the fourth most common malignancy by 2030, surpassing colorectal cancer. Although prior research has indicated that suppression of ITGA7 facilitates proliferation and migration of TC cells (Guan et al. 2020), the specific molecular pathways involved have yet to be fully elucidated. In the current study, ITGA7 expression was found to be significantly reduced in both TC tissue samples and cell lines relative to matched normal controls. This finding was further substantiated by a series of functional assays, which revealed that downregulation of ITGA7 led to enhanced proliferation, migration, and invasion of TC cells, accompanied by a significant reduction in apoptotic activity. These outcomes are consistent with previous studies, reinforcing the potential tumor-suppressive role of ITGA7 in TC. Notably, a previous study (Guan et al. 2020) found that knockdown of ITGA7 effectively simulates the gene-deficient state in TC and significantly induces malignant phenotypes. This is consistent with the observations in the present study, further supporting the key role of ITGA7 as a tumor suppressor in TC progression. FN1, a key ECM component, mediates cancer cell proliferation, adhesion, and metastasis. Elevated FN1 expression in TC has been widely reported to drive TC progression, consistent with its role in other cancers. In this study, FN1 knockdown validated its pro-tumorigenic effects in TC, supporting earlier reports. Notably, FN1 was found to interact with ITGA7, collectively influencing TC development. Given that FN1 binds specifically to integrins to regulate tumor progression (Xu et al. 2023; Kennelly et al. 2019), this study further investigated their interplay in TC. Although this study did not use exogenous FN1 protein to directly treat KTC-1 cells, functional assays showed that FN1 knockdown significantly inhibited cell proliferation, migration, and invasion, and reduced the expression levels of p-PI3K and p-AKT. Co-IP verified their physical interaction, while IF demonstrated their co-localization. Given that integrins activate downstream pathways such as AKT, ITGA7 silencing increased FN1, p-PI3K, and p-AKT. Rescue experiments further established that ITGA7 orchestrates TC progression via FN1-dependent PI3K/AKT pathway modulation. Specifically, the results indicated that knockdown of ITGA7 promotes TC cell proliferation, migration, and invasion, inhibits cell apoptosis, and activates the PI3K/AKT pathway. Importantly, FN1 silencing abrogated these ITGA7-driven effects, highlighting its pivotal role in PI3K/AKT pathway activation. To determine whether the effect of ITGA7 on TC progression in vivo was consistent with in vitro findings, a xenograft tumor experiment was conducted in nude mice. The results demonstrated that silencing ITGA7 significantly increased both tumor volume and weight compared with the control group. Western blot and IHC were performed to evaluate the expression levels of key proteins in the PI3K/AKT pathway within the tumor tissues. The results indicated markedly increased protein expression of FN1, p-PI3K, and p-AKT in the ITGA7-silenced group, which aligned with the in vitro experimental outcomes. Although the present study confirmed that ITGA7 and FN1 regulate TC progression through the PI3K/AKT signaling pathway, several limitations exist. First, this study was mainly based on the KTC-1 cell line. Although this cell line is commonly used in TC mechanism studies, its poorly differentiated characteristics may differ from PTC; therefore, validation in more differentiated cell lines (e.g., TPC-1, BCPAP, 8505C) is needed in the future. Second, the upstream mechanisms underlying ITGA7 downregulation in PTC (such as promoter methylation or non-coding RNA regulation) have not been explored. Third, the in vivo experiment used only a subcutaneous xenograft model rather than an orthotopic model or PDX model, which may not fully reflect the tumor microenvironment. Fourth, the clinical sample size was small (30 cases) and derived from a single center. Fifth, this study mainly employed knockdown strategies for ITGA7 and FN1, and overexpression experiments for ITGA7 and FN1 were not performed. Future studies should establish ITGA7- and FN1-overexpressing cell lines to further verify their inhibitory effects on tumor phenotypes. Although the knockdown results suggest that low ITGA7 expression and high FN1 expression have pro-tumorigenic effects, direct evidence from overexpression is lacking, and a comprehensive understanding of FN1-mediated regulation of TC malignant phenotypes remains to be supplemented. Despite these limitations, this study reveals for the first time that ITGA7 suppresses TC progression by binding to FN1 and inhibiting the PI3K/AKT pathway, providing an important foundation for future research. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1. Acknowledgements Not applicable. Author contributions Hui Yu and Lei Chen designed the research study. Hui Yu and Lei Chen performed the research. Tao Ma and QiLun Liu provided help and advice. Tao Ma, QiLun Liu and FaXuan Wang analyzed the data. Hui Yu and Lei Chen wrote the manuscript. FaXuan Wang reviewed and edited the manuscript. All authors contributed to editorial changes in the manuscript. All authors read and approved the final manuscript. Funding Yinchuan City Science and Technology Program Project (Soft Science)/2024RKX011. Availability of data and materials The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request. Declarations Competing interests The authors have no conflicts of interest to declare. Ethical approval The present study was approved by the Ethics Committee of General Hospital of Ningxia Medical University and written informed consent was provided by all patients prior to the study start. All procedures were performed in accordance with the ethical standards of the Institutional Review Board and The Declaration of Helsinki, and its later amendments or comparable ethical standards. All animal experiments were complied with the ARRIVE guidelines and performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. The experiments were approved by the Institutional Animal Care and Use Committee of General Hospital of Ningxia Medical University. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Hui Yu and Lei Chen have contributed equally to this work. References Associated Data Data Availability Statement The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.